- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced non-clear cell variant renal cell carcinoma
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 809KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 277KB)
Cabozantinib – March 2024
Cabozantinib (non-clear cell RCC): Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
Last updated
30 May 2025